NCT03567551

Brief Summary

This is a research study designed to help identify preeclampsia in pregnant women earlier, and possibly lead to better treatment for women preeclampsia.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
126

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started May 2017

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 15, 2017

Completed
1 year until next milestone

First Submitted

Initial submission to the registry

May 21, 2018

Completed
1 month until next milestone

First Posted

Study publicly available on registry

June 26, 2018

Completed
1.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 13, 2020

Completed
1.7 years until next milestone

Study Completion

Last participant's last visit for all outcomes

September 15, 2021

Completed
Last Updated

January 21, 2022

Status Verified

January 1, 2022

Enrollment Period

2.7 years

First QC Date

May 21, 2018

Last Update Submit

January 19, 2022

Conditions

Keywords

PreeclampsiaPregnancyComplicationsEclampsiaAquaporinAquaporin 4

Outcome Measures

Primary Outcomes (6)

  • Aquaporin 4 protein fragments in maternal blood plasma

    The investigators plan to perform targeted testing for markers that the investigators predict based on their findings or based on available published evidence

    Between hospital admission and prior to epidural or combined spinal/epidural anesthesia

  • S100B protein fragments in maternal blood plasma

    The investigators plan to perform targeted testing for markers that The investigators predict based on their findings or based on available published evidence

    Between hospital admission and prior to epidural or combined spinal/epidural anesthesia

  • Aquaporin 4 protein fragments in cerebrospinal fluid

    The investigators plan to perform targeted testing for markers that the investigators predict based on their findings or based on available published evidence

    At the time of spinal or combined spinal/epidural anesthesia

  • S100B protein fragments in cerebrospinal fluid

    The investigators plan to perform targeted testing for markers that the investigators predict based on their findings or based on available published evidence

    At the time of spinal or combined spinal/epidural anesthesia

  • Aquaporin 4 protein fragments in cord blood and placental samples

    The investigators plan to perform targeted testing for markers that the investigators predict based on their findings or based on available published evidence

    Between delivery and 2 hours after delivery

  • S100B protein fragments in cord blood and placental samples

    The investigators plan to perform targeted testing for markers that the investigators predict based on their findings or based on available published evidence

    Between delivery and 2 hours after delivery

Secondary Outcomes (3)

  • Fatty acids in maternal blood

    Between hospital admission and prior to epidural or combined spinal/epidural anesthesia

  • Fatty acids in cord blood and placental samples

    Between immediately post-delivery and 2 hours after delivery

  • Fatty Acids in cerebrospinal fluid

    during epidural or combined spinal/epidural anesthesia

Study Arms (3)

Women w/ Preeclampsia w/o Visual Disturbances or Headache

Preeclampsia Without either Visual Disturbances or Headaches Blood Pressure: \>Systolic 160 or Diastolic 110

Other: Women w/ Preeclampsia w/o Visual Disturbances or Headache

Women w/ Preeclampsia w/ Visual Disturbances or Headaches

Preeclampsia With either Visual Disturbances or Headaches Blood Pressure: \>Systolic 160 or Diastolic 110

Other: Women w/ Preeclampsia w/ Visual Disturbances or Headaches

Women w/o Preeclampsia

Normal Pregnancy Blood Pressure: \<140/90

Other: Women w/o Preeclampsia

Interventions

Up to three maternal blood samples collected from each participant, cerebrospinal fluid collected from each participant during spinal or combined spinal/epidural anesthesia, one umbilical cord blood sample obtained from each participant, four placenta samples obtained from each placenta from each participant

Women w/ Preeclampsia w/o Visual Disturbances or Headache

Up to three maternal blood samples collected from each participant, cerebrospinal fluid collected from each participant during spinal or combined spinal/epidural anesthesia, one umbilical cord blood sample obtained from each participant, four placenta samples obtained from each placenta from each participant

Women w/ Preeclampsia w/ Visual Disturbances or Headaches

Up to three maternal blood samples collected from each participant, cerebrospinal fluid collected from each participant during spinal or combined spinal/epidural anesthesia, one umbilical cord blood sample obtained from each participant, four placenta samples obtained from each placenta from each participant

Women w/o Preeclampsia

Eligibility Criteria

Age20 Years - 65 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Women older than 20 years of age, who meet all inclusion criteria and none of the exclusion criteria, and who are willing and able to sign informed consent documentation, as well as receive a combined spinal/epidural, or a spinal anesthesia regimen.

You may qualify if:

  • Greater than or equal to 20 years of age
  • Greater than 24 weeks of gestation
  • Obstetrics/Anesthesia Team had decided that Combined Spinal/Epidural (CSE) or Spinal Anesthesia will be performed

You may not qualify if:

  • Pre-pregnancy comorbidities:
  • hypertension, diabetes, or pulmonary hypertension
  • use of steroids, beta blockers, Ca channel antagonist, anticoagulants
  • cardiac or vascular conditions
  • severe headaches or visual disturbances
  • Inability to receive CSE or Spinal Anesthesia
  • Chorioamnionitis, fever, bronchitis, pneumonia

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Alabama at Birmingham

Birmingham, Alabama, 35294, United States

Location

MeSH Terms

Conditions

Pre-EclampsiaEclampsia

Condition Hierarchy (Ancestors)

Hypertension, Pregnancy-InducedPregnancy ComplicationsFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital Diseases

Study Officials

  • Tekuila Carter, MD

    University of Alabama at Birmingham

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

May 21, 2018

First Posted

June 26, 2018

Study Start

May 15, 2017

Primary Completion

January 13, 2020

Study Completion

September 15, 2021

Last Updated

January 21, 2022

Record last verified: 2022-01

Locations